How Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025

Stock Information for BioVaxys Technology Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVaxys Technology Corp.

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm(TM) for the Treatment of Severe Allergic Reactions
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm(TM) (epinephrine) Sublingual Film
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.